

SPEXIS AG CHF0.02

ISIN: CH0106213793 WKN: 10621379 Asset Class: Stock

Company

2024/06/28 17:30:02

Price

0.04 CHF

Difference ▲ 0.00%(0.00)

Contact Details

SPEXIS LTD.

Tel: +41-61-567-16-00

--


Fax: +41-61-567-16-01

Hegenheimermattweg 125

Web: <http://spexisbio.com>

4123 Allschwil

E-mail: info@spexisbio.com



Company Profile

Spexis Ltd. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of respiratory therapeutics. The firm focuses on rare, chronic respiratory diseases (CRD) and chronic lung infections in cystic fibrosis. Its product pipeline includes ColiFin, Inhaled Murepavadin, Balixafortide (POL6326), OMPPTA, EBX-002, and POL6014 (Lonodelestat). The company was founded by Daniel Obrecht and Jean-Pierre Obrecht in 1996 and is headquartered in Allschwil, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures | 2023 | | 2022 | | 2021 | |
|---------------------------------------|------------|------------------------|------------|------------------------|------------|------------------------|
| | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 3,286,000 | | 3,087,000 | | 18,295,000 | |
| Common stock capital | | 1,179,000 | | 975,000 | | 951,000 |
| Fixed assets | 13,491,000 | | 26,863,000 | | 31,601,000 | |
| Equity capital of a company | | 2,287,000 | | 19,401,000 | | 30,223,000 |
| Cash and cash equivalents | 511,000 | | 1,804,000 | | 14,368,000 | |
| Accrued liabilities | | - | | 0 | | 4,180,000 |
| Other assets | - | | - | | - | |
| Current liabilities | | 8,714,000 | | 6,002,000 | | 9,845,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 5,775,000 | | 4,547,000 | | 9,827,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 0 | | 0 | | 0 |
| Total assets | 16,777,000 | 16,777,000 | 29,951,000 | 29,951,000 | 49,897,000 | 49,897,000 |

Balance notes

| | 2023 | 2022 | 2021 |
|----------------------------|---------|--------|--------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | - | 28 | 50 |
| Equity ratio | 13.64% | 64.78% | 60.79% |
| Debt-equity ratio | 633.36% | 54.37% | 64.51% |

Others

| | 2023 | 2022 | 2021 |
|-------------------------|-------|-------|-------|
| Tax Expense Rate | 0.00% | 0.00% | 0.00% |

SPEXIS AG CHF0.02

ISIN: CH0106213793 WKN: 10621379 Asset Class: Stock

Income statement

| | 2023 | 2022 | 2021 |
|---|-------------|-------------|-------------|
| Turnover | 0 | 0 | 0 |
| Net income | -19,618,000 | -18,553,000 | -11,861,000 |
| EBIT | -19,667,297 | -19,194,203 | -10,867,175 |
| Operating income before taxes | -19,618,000 | -18,553,000 | -11,861,000 |
| Cash Flow | - | -12,118,000 | -1,149,000 |
| Net interest income | -762,000 | -150,000 | -1,442,000 |
| Research and development expenses | 12,232,000 | 9,768,000 | 875,000 |
| Income taxes | - | 0 | 0 |
| Result from investments in subsidiaries, associates and other | - | 0 | 0 |
| Revenues per employee | - | 0 | 0 |

Board of Directors

| | |
|-----------------|------------------------------------|
| Dan Hartman | Member of the administrative board |
| Dennis Ausiello | Member of the administrative board |
| Kuno Sommer | Member of the administrative board |
| Robert Clarke | Member of the administrative board |
| Bernard Bollag | Member of the administrative board |

Members of Management Board

| | |
|------------------|-------------------------------|
| Jeffrey D. Wager | Chairman of Managing Board |
| Jürgen Fröhlich | Member of Executive Committee |